In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations
Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)-piperazin-2-one), is a new dipeptidyl peptidase IV inhibitor used for the treatment of type II diabetes mellitus. The in vitro metabolic pathways of evogliptin were identified in human hepatocytes, liver microsom...
Main Authors: | Hyeon-Uk Jeong, Ju-Hyun Kim, Dae Young Lee, Hyun Joo Shim, Hye Suk Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/20/12/19808 |
Similar Items
-
Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
by: Jin Hyun Kim, et al.
Published: (2020-09-01) -
Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
by: Won-Gu Choi, et al.
Published: (2020-03-01) -
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
by: Hwang I, et al.
Published: (2020-10-01) -
Response of Three Kinds of Detoxifying Enzymes from Odontotermes formosanus (Shiraki) to the Stress Caused by Serratia marcescens Bizio (SM1)
by: XiaoYu Lu, et al.
Published: (2021-04-01) -
Corydaline Inhibits Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes
by: Hyun Joo Shim, et al.
Published: (2011-08-01)